BioSpace News Archive

Theralink Technologies , Inc. (OTC: THER) (“Theralink”) and IMAC Holdings, Inc. today announced that they have entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) under which Theralink will merge with a newly-formed wholly-owned subsidiary of IMAC in a stock-for-stock reverse merger transaction (the “Merger”) in which Theralink will survive as a wholly-owned subsidiary of IMAC, a Nasdaq-listed company.

Harbinger Health, a biotechnology company pioneering the detection of early cancer, announced the appointment of May Orfali, M.D., as Chief Medical Officer.

ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems, announced that a leading pharmaceutical company in Brazil selected ValGenesis iRisk to redefine and automate the company’s risk-based validation processes.

Stereotaxis, the global leader in robotic technologies for the treatment of cardiac arrhythmias, announced the first treatment of patients with a newly launched Genesis Robotic Magnetic Navigation system at Advocate Christ Medical Center in Chicago, Illinois.

.Radiopharmaceuticals have recently been making headlines due to their potential in medical imaging and targeted therapies.

To better explain the prevalence and cause of clots, researchers from The Feinstein Institutes for Medical Research investigated the rates of clotting 90 days after patients leave the hospital.

Quest Diagnostics is proud to support Americares in their efforts to improve health for people affected by poverty or disaster with a grant from Quest for Health Equity.

Mereo BioPharma Group plc announced that data from the Phase 2 “ASTRAEUS” trial of alvelestat for the treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease, as well as post-hoc analyses demonstrating the association between biomarker reductions with alvelestat and improvements in SGRQ were presented for the first time to the scientific community at the 2023 American Thoracic Society International Conference.

The Ivy Brain Tumor Center and Barrow Neurological Institute are pleased to announce the addition of Yoshie Umemura, MD, as the new Chief Medical Officer of the Ivy Brain Tumor Center and Chief of Neuro-Oncology and the William and Joan Shapiro Chair of Neuro-Oncology at Barrow Neurological Institute.

The EROS study is the first real-world evidence analysis of BREZTRI in more than 2,400 patients with COPD from a claims database registry, and was presented as a late-breaking abstract at the ATS 2023 International Conference in Washington, DC, hosted by the American Thoracic Society.